ENTITY
SinoMab Bioscience

SinoMab Bioscience (3681 HK)

13
Analysis
Health CareHong Kong
SinoMab Bioscience is a clinical-stage biopharmaceutical company focused on the research, development, manufacturing, and commercialization of monoclonal antibody-based therapeutics for immunological diseases. Its flagship product, SM03 (Suciraslimab), targets rheumatoid arthritis and other autoimmune conditions. The company was founded in 2001 and is headquartered in Hong Kong.
more
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
x